Compare VNRX & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | AYTU |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 25.7M |
| IPO Year | 2012 | 2015 |
| Metric | VNRX | AYTU |
|---|---|---|
| Price | $0.20 | $2.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $2.50 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 12.0M | 44.8K |
| Earning Date | 03-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,233,511.00 | ★ $27,632,080.00 |
| Revenue This Year | $68.22 | N/A |
| Revenue Next Year | $382.75 | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 59.10 | ★ 277.47 |
| 52 Week Low | $0.17 | $0.95 |
| 52 Week High | $0.94 | $3.07 |
| Indicator | VNRX | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | 55.43 |
| Support Level | $0.17 | $2.14 |
| Resistance Level | $0.27 | $2.66 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 21.99 | 62.50 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.